9 Facts About NMN and NAD Precursors Before You Spend Money on Them for Menopause Energy and Aging
The fatigue that hits in perimenopause is so real and so relentless that when something promises to 'recharge your cells at the source,' it is incredibly hard not to reach for it. The NMN hype found me at exactly the right moment of exhaustion. What kept me from diving in was realising the studies I kept seeing cited were almost entirely in mice — and that the human trials, while promising, were far too small and short to justify the price tag or the certainty of the marketing claims.
Learn more about Rose →NAD+ is a real and important molecule — the biology behind the hype is not invented
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell in the body and is essential for energy metabolism, DNA repair, and the activity of proteins called sirtuins that regulate cellular stress responses. NAD+ levels do decline measurably with age in human tissue, a fact established in peer-reviewed research, not marketing copy. This legitimate biological reality is what the supplement industry has built an enormous commercial structure around — which does not automatically mean the supplements work, but it does mean the premise is not nonsense.
Most of the dramatic results come from rodent studies, and mice are not small humans
The studies showing NMN reversing muscle decline, improving metabolism, restoring fertility, and extending lifespan were conducted almost entirely in mice, and many used doses that do not translate proportionally to a practical human equivalent. Rodent NAD metabolism differs from human NAD metabolism in meaningful ways, and mice have a far shorter lifespan, making age-related interventions easier to measure. Supplement marketing routinely presents these findings as though they predict human outcomes, which is a significant overreach of what the science currently supports.
Human clinical trials exist but are small, short, and mostly measure blood levels rather than symptoms
Several randomised controlled trials have confirmed that oral NMN and NR do raise NAD+ levels in human blood — that part works. However, most of these trials enrolled between 12 and 60 participants, ran for 8 to 12 weeks, and used NAD+ concentration in blood as the primary outcome, not energy levels, cognitive function, muscle strength, or menopausal symptom scores. Raising a biomarker in the blood is not the same as demonstrating a clinical benefit that a person would actually notice in daily life.
The menopause-specific connection is largely theoretical, not studied
Oestrogen plays a role in NAD+ metabolism, and some researchers have hypothesised that the hormonal shift of perimenopause may accelerate NAD+ decline — making supplementation potentially more relevant for this life stage than for younger women. This is a plausible and interesting hypothesis, but as of now there are no published clinical trials specifically recruiting perimenopausal or postmenopausal women and measuring meaningful menopause symptom outcomes. The menopause marketing angle is extrapolated from general aging research, not from studies done in this population.
NMN and NR are different molecules with different absorption pathways — they are not interchangeable
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both NAD+ precursors but they enter cells via different transporters and conversion pathways, meaning results from NR studies cannot simply be applied to NMN products and vice versa. NMN requires a specific small intestinal transporter called Slc12a8, and whether this transporter functions the same way in humans as in mice has been a matter of genuine scientific debate. Consumers comparing products across the two categories should be aware they are not reading from a shared evidence base.
The energy benefits most women are hoping for have more robustly evidenced alternatives
The fatigue and low energy that are among the most disabling symptoms of perimenopause are well-documented and have several interventions with substantially stronger human evidence behind them, including menopausal hormone therapy, resistance exercise, sleep optimisation, and addressing thyroid function or iron deficiency if present. Before attributing fatigue to declining NAD+ and spending significantly on supplements, it is worth methodically ruling out and addressing the causes with the clearest evidence first. NMN is not a substitute for that process.
Long-term safety data in humans simply does not exist yet
The longest human trials of NMN supplementation published to date have run for around 12 weeks, which is not nearly enough time to identify risks that emerge with years of continuous use. NAD+ pathway manipulation affects sirtuin activity, PARP enzymes involved in DNA repair, and CD38 — pathways with complex roles in immune function and cancer biology — and the downstream effects of chronically elevating NAD+ in living humans are genuinely unknown. This is not a reason to assume danger, but it is a reason to treat the absence of safety signals in short trials as something other than a green light.
Supplement quality and dosing are unregulated and highly variable across products
Because NMN and NR are sold as dietary supplements rather than regulated medicines in most countries, there is no mandatory verification that a capsule contains what the label claims, in the quantity stated, or free from contaminants. Independent testing by third-party organisations has found meaningful discrepancies between labelled and actual NMN content in commercially available products. Even in the human trials that did show NAD+ elevation, the doses used were specific and controlled — buying an unverified product at an arbitrary dose does not replicate trial conditions.
The research field is moving quickly — checking back in two to three years is a genuinely reasonable strategy
Several larger, longer, and better-powered human trials of NMN and NR are currently underway, including trials specifically looking at muscle function, metabolic health, and cognitive outcomes in older adults. The science is not stalled — it is in an active phase that may produce much clearer answers within a few years, at which point the cost-benefit calculation could look very different. For women who are not dealing with urgent, debilitating symptoms, waiting for that evidence to mature before committing to an expensive monthly supplement is a completely rational and evidence-consistent position to take.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.